Statement: The most common adverse event in cohort 1 of the primary trial is Neutropenia.
Primary_evidence: Adverse Events 1:   Total: 21/337 (6.23%)   Blood/Bone Marrow-Other 0/337 (0.00%)   Febrile neutropenia 0/337 (0.00%)   Hemoglobin 2/337 (0.59%)   Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%)   Cardiac-ischemia/infarction 1/337 (0.30%)   Left ventricular diastolic dysfunction 0/337 (0.00%)   Left ventricular systolic dysfunction 1/337 (0.30%)   Restrictive cardiomyopathy 1/337 (0.30%) Adverse Events 2:   Total: 48/348 (13.79%)   Blood/Bone Marrow-Other 1/348 (0.29%)   Febrile neutropenia 1/348 (0.29%)   Hemoglobin 1/348 (0.29%)   Atrioventricular block - 2nd degree Mobitz Type II 1/348 (0.29%)   Cardiac-ischemia/infarction 2/348 (0.57%)   Left ventricular diastolic dysfunction 1/348 (0.29%)   Left ventricular systolic dysfunction 0/348 (0.00%)   Restrictive cardiomyopathy 0/348 (0.00%)